Massive Bio expands European operations with 3 new hires

Massive Bio, which matches patients with cancer trials, made three key hires as part of its plans to expand European operations.

The hires are part of the company’s growth strategy that is being funded by a $9 million investment infusion it received in June. That funding was led by Revo Capital and Kenan Turnacioğlu, chair of the board of directors at PaigeAI, with additional participation from German development finance institution DEG.

Joining Massive Bio are Toygun Onaran as head of strategy, Mert Sari as regional manager and Sinan Fındık as clinical research and data manager. The trio is part of Massive Bio’s focus on expanding global operations, ramping up marketing activities, developing new data sets and products and expanding its M&A efforts.

“With the steps we have taken in the last two years, we have ensured that thousands of cancer patients in Spain, Italy, France, Germany, Romania, Poland and Greece are matched to appropriate clinical trials,” Çağlar Demirbağ, the company’s director of international partnerships outside of the U.S., said in a statement. 

New York-based Massive Bio boasts partnerships with 26 pharma companies and CROs, with more than 1,000 global clinical research centers spanning 12 countries. 

By using its AI clinical trial matching program, Massive Bio aims to enroll 100,000 cancer patients by expanding to 19 countries as part of its 100K Cancer Clinical Trial Singularity Program, which the company announced last year. So far, more than 66,000 patients have been reached by its clinical trial matching.